Search

Search Results

• A Phase II international, multicenter study of oral panobinostat (LBH589) in patients with refractory cutaneous T-cell lymphoma

  MG Bernengo, F Vanaclocha, M Duvic, T Kuzel, F Kerdel, L Pinter-Brown, A Bosly, C Okada, D Breneman, PL Zinzani, J Becker, L Hughey, M Ardaiz, J Zain, L Zhang

  2009-06-23

  Published: June 23, 2009

  183

  PDF: 192

• Histone deacetylase inhibitors: SAHA (Vorinostat). A treatment option for advanced cutaneous T-cell lymphoma

  M Duvic

  2009-06-23

  Published: June 23, 2009

  231

  PDF: 2245

• Innovative treatments: bexarotene

  M Duvic

  2009-06-11

  Published: June 11, 2009

  185

  PDF: 320

• Epigenetic approaches. Histone deacetylase inhibitors: vorinostat. A new treatment option for advanced cutaneous T-cell lymphoma

  M Duvic

  2009-06-11

  Published: June 11, 2009

  247

  PDF: 321

• Optimizing bexarotene therapy for cutaneous T-cell lymphoma

  M Duvic

  2009-06-10

  Published: June 10, 2009

  228

  PDF: 714

• Optimizing denileukin diftitox (Ontak®) therapy

  M Duvic

  2009-06-10

  Published: June 10, 2009

  172

  PDF: 727

• From cell biology to therapy: forodesine

  M Duvic

  2009-06-23

  Published: June 23, 2009

  372

  PDF: 731